Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 3 3Phase 1/2 3Phase 1 2Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplastic Cells, Circulating 1Carcinoma, Non-Small-Cell Lung 1

Interventions

fludarabine 5Cyclophosphamide 5Surgical Procedures, Operative 2Standard of Care 2Immune Checkpoint Inhibitors 2Bevacizumab 2venetoclax 1tucatinib 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1tislelizumab 1tipiracil 1spartalizumab 1sotorasib 1selpercatinib 1posaconazole 1pembrolizumab 1peginterferon alfa-2b 1osimertinib 1montelukast 1malic acid 1icotinib 1gallium maltolate 1encorafenib 1eliglustat 1durvalumab 1daratumumab 1cannabigerol 1asciminib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Not yet recruiting × osimertinib × Clear all
NCT06557096 2024-08-16

CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC

Second Affiliated Hospital of Nanchang University

Phase EARLY_PHASE1 Not yet recruiting
100 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplastic Cells, Circulating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡